In March 2025, BioVersys announced that the first patient has been dosed in a pulmonary TB Phase 2 clinical trial, evaluating the early bactericidal activity (EBA) and safety of alpibectir-ethionamide ...

New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Fed Governor Adriana Kugler noted that a reversal in trend in goods inflation recently was an "unhelpful" development. Read ...

As we settle into a new year, the global initial public offering landscape presents a fascinating tapestry of challenges and ...

This was seen recently in January 2025, when GSK (LSE/NYSE: GSK) acquired IDRx, a Boston-based biotech specializing in precision therapies for gastrointestinal stromal tumors (GIST). Initially, GSK ...

California's luxury real estate market tells a fascinating story of wealth, migration, and changing lifestyles. Between 2018 ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

The Hong Kong University of Science and Technology (HKUST) and Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC) together announced the ...

Many experts — be they venture capitalists or private equity investors — shared their advice with biotech entrepreneurs ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...